Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$37.66 USD

37.66
184,435

+0.09 (0.24%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $37.66 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Products

Zacks News

Here's Why You Should Hold on to Surmodics (SRDX) Stock Now

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio Now

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Surmodics (SRDX) Beats on Q3 Earnings, Revises FY22 View

Product sales primarily drive Surmodics' (SRDX) third-quarter top-line growth. However, the company expects softer demand for its products and services in the second half of 2022.

SurModics (SRDX) Reports Q3 Loss, Misses Revenue Estimates

SurModics (SRDX) delivered earnings and revenue surprises of 12.82% and 2.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Here's Why You Should Hold on to Surmodics (SRDX) Stock For Now

Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.

Haemonetics (HAE) Up 28.2% Since Last Earnings Report: Can It Continue?

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Surmodics (SRDX) Beats on Q2 Earnings, Revises FY22 View

Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.

SurModics (SRDX) Reports Q2 Loss, Tops Revenue Estimates

SurModics (SRDX) delivered earnings and revenue surprises of 31.25% and 6.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.

SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates

SurModics (SRDX) delivered earnings and revenue surprises of 63.89% and 3.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate SurModics (SRDX) to Report a Decline in Earnings: What to Look Out for

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Surmodics (SRDX) Stock Loses 2.2% Despite Q4 Earnings Beat

Surmodics' (SRDX) fiscal fourth-quarter results reflect benefits from segmental strength.

SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates

SurModics (SRDX) delivered earnings and revenue surprises of 60.00% and 6.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate SurModics (SRDX) to Report a Decline in Earnings: What to Look Out for

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Surmodics' (SRDX) Latest Sublime Catheter Expands Patient Pool

Surmodics' (SRDX) latest addition is expected to aid in performing more complex interventions which were earlier not possible.

HRC vs. SRDX: Which Stock Is the Better Value Option?

HRC vs. SRDX: Which Stock Is the Better Value Option?

HRC vs. SRDX: Which Stock Is the Better Value Option?

HRC vs. SRDX: Which Stock Is the Better Value Option?

Surmodics' (SRDX) Q3 Earnings, Revenues Fall Shy of Estimates

Higher revenues from the IVD segment drives Surmodics' (SRDX) fiscal third-quarter top line.

SurModics (SRDX) Reports Q3 Loss, Misses Revenue Estimates

SurModics (SRDX) delivered earnings and revenue surprises of -54.55% and -0.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: SurModics (SRDX) Q3 Earnings Expected to Decline

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HRC vs. SRDX: Which Stock Should Value Investors Buy Now?

HRC vs. SRDX: Which Stock Is the Better Value Option?

Surmodics (SRDX) Boosts Portfolio With Vetex Medical Buyout

Surmodics' (SRDX) buyout of Vetex Medical adds second FDA 510 (k) cleared device to its thrombectomy platform.

HRC vs. SRDX: Which Stock Is the Better Value Option?

HRC vs. SRDX: Which Stock Is the Better Value Option?

EYE or SRDX: Which Is the Better Value Stock Right Now?

EYE vs. SRDX: Which Stock Is the Better Value Option?